Inflamed phenotype of splenic marginal zone B-cell lymphomas with expression of PD-L1 by intratumoral monocytes/macrophages and dendritic cells-Reference-Cited by-同舟云学术

Inflamed phenotype of splenic marginal zone B-cell lymphomas with expression of PD-L1 by intratumoral monocytes/macrophages and dendritic cells

Published:2019-04-09 Issue:6 Volume:16 Page:621-624
ISSN:1672-7681
Container-title:Cellular & Molecular Immunology
language:en
Short-container-title:Cell Mol Immunol

Author:

Vincent-Fabert Christelle,Soubeyran Isabelle,Velasco Valérie,Parrens Marie,Jeannet Robin,Lereclus Emilie,Gachard Nathalie,Feuillard Jean^ORCID,Faumont Nathalie

Funder

Ligue Contre le Cancer

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Link

http://www.nature.com/articles/s41423-019-0228-y.pdf

Reference15 articles.

1. Thieblemont, C. et al. Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. Lancet. Oncol. 4, 95–103 (2003).

2. Berger, F. et al. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood 95, 1950–1956 (2000).

3. Petit, B. et al. Among 157 marginal zone lymphomas, DBA.44(CD76) expression is restricted to tumour cells infiltrating the red pulp of the spleen with a diffuse architectural pattern. Histopathology 54, 626–631 (2009).

4. Perrone, S. et al. Splenic marginal zone lymphoma: prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era. Leuk. Res. 44, 53–60 (2016).

5. Casulo, C. & Friedberg, J. Transformation of marginal zone lymphoma (and association with other lymphomas). Best. Pract. Res. Clin. Haematol. 30, 131–138 (2017).

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The genomic and molecular landscape of splenic marginal zone lymphoma, biological and clinical implications;Exploration of Targeted Anti-tumor Therapy;2024-07-23

2. Mesenchymal stem cells-macrophages crosstalk and myeloid malignancy;Frontiers in Immunology;2024-05-08

3. Mechanism of Action and Pharmacologic Features of Drugs Targeting PD ‐1/ PDL ‐1 and CTLA ‐4;Precision Cancer Therapies vol 2 ‐ Immunologic Approaches for the Treatment of Lymphoid Malignancies ‐ From Concept to Practice;2024-02-21

4. B-cell specific expression of the murineMyd88^L252Pmutation correlates with the establishment of an immunosuppressive microenvironnement in Waldenström macroglobulinemia lymphoplasmacytic lymphoma;2023-09-29

5. Role and Mechanisms of Tumor-Associated Macrophages in Hematological Malignancies;Frontiers in Oncology;2022-07-07